Price T Rowe Associates Inc Bei Gene, Ltd. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,020,127 shares of BGNE stock, worth $231 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,020,127
Previous 2,713,418
62.4%
Holding current value
$231 Million
Previous $739 Million
66.56%
% of portfolio
0.03%
Previous 0.09%
Shares
19 transactions
Others Institutions Holding BGNE
# of Institutions
268Shares Held
32.2MCall Options Held
113KPut Options Held
106K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion20.22% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Capital International Investors Los Angeles, CA4.89MShares$1.11 Billion0.2% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million9.68% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.01MShares$229 Million1.13% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...